[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344754-105":59,"doc-detail-344754-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","obstacles-and-improvement-strategies-for-car-t-cell-therapy-in-solid-tumors","Obstacles and improvement strategies for CAR-T cell therapy in solid tumors","","CAR-T cell therapy genetically equips patients’ T cells with chimeric antigen receptors (CARs) to target cancer. While highly effective in hematologic malignancies, translation to solid tumors is constrained by limited infiltration, an immunosuppressive tumor microenvironment, and metabolic barriers. This review surveys actionable CAR-T targets in solid tumors and evaluates innovative approaches to increase penetration, persistence, and cytotoxic function through advanced CAR designs, combination regimens, and metabolic-resilience strategies, highlighting the field’s future potential.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/obstacles-and-improvement-strategies-for-car-t-cell-therapy-in-solid-tumors/344754/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/obstacles-and-improvement-strategies-for-car-t-cell-therapy-in-solid-tumors/344754.png","ImageObject",300,407,{"name":92,"@type":93},"Anda","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-08","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What are the main obstacles for CAR-T cell therapy in solid tumors?","Question",{"text":113,"@type":114},"Solid tumors limit CAR-T infiltration due to physical and biological barriers, create an immunosuppressive tumor microenvironment, and introduce metabolic obstacles, alongside issues like antigen loss and toxicity.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What strategies does the review discuss to improve CAR-T performance in solid tumors?",{"text":118,"@type":114},"It examines advanced CAR designs, combination therapies, and methods intended to enhance tumor penetration, survival, and cytotoxicity despite metabolic competition.",{"name":120,"@type":111,"acceptedAnswer":121},"How do fourth- and fifth-generation CARs differ from earlier generations?",{"text":122,"@type":114},"Fourth-generation CAR-T cells can secrete specific proteins such as cytokines, while fifth-generation CARs incorporate cytokine receptor domains (e.g., IL-2Rβ) to support self-activation.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},344754,1790159934,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962075006959,"https://ap-avatar.wpscdn.com/avatar/e0002397efbe92a78e?_k=1776741047341049297","Luo etal. Discover Oncology (2026) 17:271 [https://doi.org/10.1007/s12672-026-04473-8](https://doi.org/10.1007/s12672-026-04473-8)  \nDiscover Oncology  \nREVIEW Open Access  \nObstacles and improvement strategies for CAR-T cell therapy in solid tumors  \nZhihao Luo1, Qian Hu1, Meng Ren2, Li Wang1, Qingshuang Zou3, Xiaosha Wen3, Shang Chen4, Quan Liu3, Dixian Luo3,5 and Zifen Guo1*  \n*Correspondence: Zifen Guo [guozifen76@163.com](guozifen76@163.com)  \nFull list of author information is available at the end of the article  \nAbstract  \nCAR-T cell therapy, which genetically modifies a patient’s T cells to express chimeric antigen receptors (CARs), has shown remarkable efficacy in treating blood cancers. However, its application to solid tumors is hindered by challenges such as inadequate tumor infiltration, an immunosuppressive microenvironment, and metabolic obstacles. This review explores potential targets for CAR-T cells in solid tumors and examines innovative strategies to enhance their tumor penetration, survival, and cytotoxicity. These include advanced CAR designs, combination therapies, and methods to improve CAR-T cell function amidst metabolic competition. As research and technology progress, CAR-T therapy holds promise as a viable option for solid tumor treatment, with future efforts emphasizing interdisciplinary collaboration to unlock its full potential.  \nKeywords CAR-T, Solid tumor, Antigen escape, Immunosuppressive microenvironment, Metabolic competition, Immunotherapy  \n1 Introduction  \nCAR-T therapy is a cutting-edge immunotherapy that utilizes the patient’s own immune system. This innovative treatment involves extracting T cells from the patient’s body, genetically modifying them to have specific antigen receptors (CARs) on their surface, enabling them to precisely identify and bind to tumor cells that express the corresponding antigens. After these modified cells are multiplied extensively in laboratory conditions, they are reintroduced into the patient’s bloodstream, where they go on the offensive against cancerous cells, essentially turning the body’s own immune defenses into a targeted strike force against tumors [1]. CAR T cells have five generations of structure. The initial iteration of CAR T-cell therapy incorporates a single-chain variable fragment (ScFv) designed to identify extracellular antigens. This construct comprises both light and heavy chains along with an intracellular T-cell activation segment derived from CD3ζ. Building upon this initial framework, the next-generation CAR incorporates an extra intracellular costimulatory domain, which may include either CD28 or 4-1BB signaling elements. The third generation takes it a step further by integrating both the  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by-nc-nd/4.0/.  \nLuo et al. Discover Oncology (2026) 17:271 Page 2 of 29  \nCD28 and 4-1BB signaling domains, enhancing the overall functionality [2]. Recent advancements in CAR-T cell engineering hav","cbCaiopBPcUitGkj","https://ap.wps.com/l/cbCaiopBPcUitGkj","pdf",1915845,29,"English","# Introduction\n## CAR-T generations and design evolution\n## Challenges in solid tumors","[{\"question\":\"What are the main obstacles for CAR-T cell therapy in solid tumors?\",\"answer\":\"Solid tumors limit CAR-T infiltration due to physical and biological barriers, create an immunosuppressive tumor microenvironment, and introduce metabolic obstacles, alongside issues like antigen loss and toxicity.\"},{\"question\":\"What strategies does the review discuss to improve CAR-T performance in solid tumors?\",\"answer\":\"It examines advanced CAR designs, combination therapies, and methods intended to enhance tumor penetration, survival, and cytotoxicity despite metabolic competition.\"},{\"question\":\"How do fourth- and fifth-generation CARs differ from earlier generations?\",\"answer\":\"Fourth-generation CAR-T cells can secrete specific proteins such as cytokines, while fifth-generation CARs incorporate cytokine receptor domains (e.g., IL-2Rβ) to support self-activation.\"}]","Obstacles and improvement strategies for CAR-T cell therapy in solid tumors | PDF",1790055147,73,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/08c400d6ffebb3c3155d234bed5bd3d7.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b6b4afb4dd938b35a33b9e0db1cc4661.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/92c8c5a16bd366916dc30c8f42b7e1e0.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e15acce30ea8601b724712e23aa10b45.webp",980,1306]